Next Article in Journal
Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs: An Update
Next Article in Special Issue
A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept
Previous Article in Journal
Mitochondrial Drugs for Alzheimer Disease
Previous Article in Special Issue
The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension
Open AccessArticle

Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?

1
Clinical Research Center for Rare Diseases “Aldo e Cele Daccò”, Villa Camozzi, Ranica, Italy
2
Department of Medicine and Transplantation, Ospedali Riuniti-Mario Negri Institute for Pharmacological Research, Bergamo, Italy
3
Division of Nephrology, Department of Medicine, University of Alabama, Birmingham, Birmingham, AL 35294, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(1), 1-9; https://doi.org/10.3390/ph3010001
Received: 2 December 2009 / Revised: 29 December 2009 / Accepted: 31 December 2009 / Published: 5 January 2010
(This article belongs to the Special Issue Antihypertensive Drugs)
We have studied the effects of add-on spironolactone treatment (100 mg/day) in 11 patients with idiopathic membranous nephropathy (IMN) and > 3 gm proteinuria/day despite angiotensin converting enzyme (ACE) inhibitor therapy titrated to a systolic/diastolic blood pressure < 120/80 mmHg. Blood pressure, 24-hour urinary protein excretion, and creatinine clearance were measured prior to, after two months of combined therapy, and after a 2-month withdrawal period of spironolactone. While systolic and diastolic blood pressure decreased significantly after spironolactone therapy, proteinuria did not improve. Serum potassium increased significantly as well, with three patients requiring resin-binding therapy. Thus, spironolactone seems to have no additional antiproteinuric effects over ACE inhibitor therapy in patients with IMN and nephrotic syndrome and carries the risk of significant hyperkalemia. View Full-Text
Keywords: idiopathic membranous nephropathy; spironolactone; proteinuria; hyperkalemia idiopathic membranous nephropathy; spironolactone; proteinuria; hyperkalemia
Show Figures

Figure 1

MDPI and ACS Style

Cravedi, P.; Brusegan, V.; Ruggenenti, P.; Campbell, R.; Remuzzi, G. Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work? Pharmaceuticals 2010, 3, 1-9.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop